While the broad market weakens, Cabot Small-Cap Confidential soldiers on, ferreting out little-known small companies with excellent growth prospects, performing exhaustive research, and then presenting the results of only the very best to our readers, limited by design to just 500. The January selection was a particularly challenging company to research; genetic engineering is a young science where we all have a lot to learn.
